Harbour Biomed and Yantai Lannacheng Biotechnology signed a long-term strategic collaboration to advance next-generation radionuclide–drug conjugates (RDCs) for cancer treatment. The partners will combine Harbour Biomed’s discovery capabilities with Lannacheng’s manufacturing and radiochemistry expertise to move RDC candidates from preclinical development toward clinical testing. The alliance targets the growing field of targeted radiotherapeutics, where companies are pairing tumor-targeting ligands with radioactive payloads. By formalizing a multi-year partnership, Harbour Biomed and Lannacheng aim to accelerate candidate selection and translational work required for first-in-human trials.